Paul Feuerstadt, MD: The Promise of RBX2660 for C Difficile

RBX2660 could make a major difference in treating recurrent Clostridioides difficile infections (rCDI).

Similar to how fecal microbiota transplantation (FMT) is a viable treatment, RBX2660 is a standardized, stabilized, investigational microbiota-based live therapeutic.

In data presented at the 2021 American College of Gastroenterology (ACG) Annual Meeting, investigators found high clinical efficacy in reducing rCDI with a sustained clinical response up to 6 months, with consistent safety results from previous clinical trials.

In the new trial, 94 patients were examined from 5 sites between November 2015 and September 2019, 64 of which were in the primary safety set with a treatment success rate of 82.8% (n = 53). There was no different between patients who received 1 dose (83.3%; n = 20) compared to 2 doses (82.5%; n = 33).

For the patients who initially responded, 88.7% ( n = 47) sustained a clinical response at 6 months.

For safety, 92.2% of the adverse events reported were deemed mild or moderate in severity, including in patients with immune-mediated or autoimmune disorders and non-specific inflammation conditions.

In an interview with HCPLive®, Paul Feuerstadt , MD, Yale University School of Medicine, explained how RBX2660 leverages new technology and why that could be an answer in treating C difficile infections.